Good physical performance is associated with better cognition in people with relapsing-remitting MS, according to a recent study by the University of Eastern Finland. Good functional capacity was also ...
15don MSN
Roche says experimental drug helped slow disability in progressive multiple sclerosis study
Roche Holdings AG RHHBY on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib. Fenebrutinib is an ...
Background Physical activity has been associated with neuroprotective and immunomodulatory benefits, potentially influencing ...
A predictive tool considering disease duration, age at disease onset, age, and Expanded Disability Status Scale score estimated patients’ risk of transition to secondary progressive multiple sclerosis ...
Treatment of pediatric-onset relapsing-remitting multiple sclerosis with high-efficacy therapy reduces the risk for transition across disability states, according to a study published in the May issue ...
The investigational therapy fenebrutinib was as effective as Ocrevus for reducing disability progression in people with PPMS, a trial showed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results